Copyright © 2005, European Society of Cardiology
Blockade of NF-
B improves cardiac function and survival without affecting inflammation in TNF-
-induced cardiomyopathy
aDepartment of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
bDepartment of Medicine, Jefferson Medical College, Philadelphia, PA, USA
* Corresponding author. Tel.: +81 92 642 5360; fax: +81 92 642 5374. Email address: kubotat{at}cardiol.med.kyushu-u.ac.jp
Objective: NF-
B, a key transcription factor that regulates inflammatory processes, has been shown to be activated in the failing human heart with enhanced expression of proinflammatory cytokines. In the present study, we assessed the hypothesis that cardiotoxic effects of proinflammatory cytokines are mediated by the activation of NF-B.
Methods: Transgenic mice with cardiac-specific overexpression of TNF-
were used as a model of cytokine-induced cardiomyopathy. To block the activation of NF-B, transgenic mice (TG/p50+/+) were crossed with knockout mice in which the p50 subunit of NF-B was disrupted (WT/p50–/–).
Results: The electrophoretic mobility shift assay demonstrated that NF-B was activated in the myocardium of TG/p50+/+ mice, while it was completely abolished in TG/p50–/– mice. Male TG mice died of congestive heart failure earlier than females, where the disruption of the p50 subunit significantly improved the survival. Compared with TG/p50+/+ mice, TG/p50–/– mice showed a significant reduction of ventricular dilatation and hypertrophy with preserved fractional shortening. Although the myocardial expression of proinflammatory cytokines or infiltration of inflammatory cells was not affected, increased expression and activity of MMP-9 were significantly suppressed in TG/p50–/– mice.
Conclusion: Blockade of NF-B activation did not ameliorate myocardial inflammation but improved cardiac function and survival in male TNF- TG mice. An inhibition of NF-B may be a new therapeutic strategy for cardiac remodeling and heart failure, especially when proinflammatory cytokines are activated.
KEYWORDS Nuclear factor-B; Cytokines; Tumor necrosis factor-; Matrix metalloproteinases; Transgenic animal models; Myocarditis; Heart failure; Cardiac remodeling
Time for primary review 23 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Hikoso, O. Yamaguchi, Y. Nakano, T. Takeda, S. Omiya, I. Mizote, M. Taneike, T. Oka, T. Tamai, J. Oyabu, et al. The I{kappa}B Kinase {beta}/Nuclear Factor {kappa}B Signaling Pathway Protects the Heart From Hemodynamic Stress Mediated by the Regulation of Manganese Superoxide Dismutase Expression Circ. Res., July 2, 2009; 105(1): 70 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. X. L. Liu, R. Tian, H. Baskind, W. Hsueh, and I. G. De Plaen Platelet-activating factor induces the processing of nuclear factor-{kappa}B p105 into p50, which mediates acute bowel injury in mice Am J Physiol Gastrointest Liver Physiol, July 1, 2009; 297(1): G76 - G81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frantz and J. Bauersachs Regarding the Article by Timmers et al Circ. Res., June 5, 2009; 104(11): e60 - e60. [Full Text] [PDF]
|
|
|
|
|
|
L. Timmers and D. P.V. de Kleijn Response to the Letter by Frantz and Bauersachs Circ. Res., June 5, 2009; 104(11): e61 - e61. [Full Text] [PDF]
|
|
|
|
|
|
L. Timmers, J. K. van Keulen, I. E. Hoefer, M. F.L. Meijs, B. van Middelaar, K. den Ouden, C. J.A. van Echteld, G. Pasterkamp, and D. P.V. de Kleijn Targeted Deletion of Nuclear Factor {kappa}B p50 Enhances Cardiac Remodeling and Dysfunction Following Myocardial Infarction Circ. Res., March 13, 2009; 104(5): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frantz, J. Tillmanns, P. J. Kuhlencordt, I. Schmidt, A. Adamek, C. Dienesch, T. Thum, S. Gerondakis, G. Ertl, and J. Bauersachs Tissue-Specific Effects of the Nuclear Factor {kappa}B Subunit p50 on Myocardial Ischemia-Reperfusion Injury Am. J. Pathol., August 1, 2007; 171(2): 507 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frantz, K. Hu, B. Bayer, S. Gerondakis, J. Strotmann, A. Adamek, G. Ertl, and J. Bauersachs Absence of NF-{kappa}B subunit p50 improves heart failure after myocardial infarction FASEB J, September 1, 2006; 20(11): 1918 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kawano, T. Kubota, Y. Monden, T. Tsutsumi, T. Inoue, N. Kawamura, H. Tsutsui, and K. Sunagawa Blockade of NF-{kappa}B improves cardiac function and survival after myocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1337 - H1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Deschamps and F. G. Spinale Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation Cardiovasc Res, February 15, 2006; 69(3): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Higuchi, T. O. Chan, M. A. Brown, J. Zhang, B. R. DeGeorge Jr., H. Funakoshi, G. Gibson, C. F. McTiernan, T. Kubota, W. K. Jones, et al. Cardioprotection afforded by NF-{kappa}B ablation is associated with activation of Akt in mice overexpressing TNF-{alpha} Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H590 - H598. [Abstract] [Full Text] [PDF]
|
|